跳至主要内容
临床试验/NL-OMON52267
NL-OMON52267尚未招募不适用

Harm reduction in anabolic androgenic steroid use - HARNAS-trial

Elisabeth-Tweesteden ziekenhuis0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Men of at least 18 years old.
  • The subjects intents to start an androgen cycle within 2 weeks after
  • enrollment.
  • The planned cycle has an average weekly dose >250 mg and duration >6 weeks.

排除标准

  • The use of AAS in the 3 months prior to enrollment (except for TRT <250
  • When in the last 6 months:
  • 1) A new somatic or psychiatric illness was diagnosed.
  • 2) A medication for chronic illness was started or changed.
  • 3) A (non-traumatic) hospital admission occured (or psychiatric ward
  • admission).

研究者

发起方
Elisabeth-Tweesteden ziekenhuis

相似试验